PRTC Stock Overview
PureTech Health plc, a clinical stage biotherapeutics company, engages in the discovery, development, and commercialization of biotechnology and pharmaceutical solutions in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
PureTech Health plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£2.13 |
| 52 Week High | UK£2.43 |
| 52 Week Low | UK£1.39 |
| Beta | 0.93 |
| 1 Month Change | -7.21% |
| 3 Month Change | 7.21% |
| 1 Year Change | 1.67% |
| 3 Year Change | -46.27% |
| 5 Year Change | 8.70% |
| Change since IPO | 19.38% |
Recent News & Updates
Recent updates
What You Need To Know About The PureTech Health plc (LON:PRTC) Analyst Downgrade Today
Aug 27
Is PureTech Health (LON:PRTC) A Risky Investment?
Apr 28Health Check: How Prudently Does PureTech Health (LON:PRTC) Use Debt?
Dec 21Is PureTech Health (LON:PRTC) Using Too Much Debt?
Aug 28PureTech Health plc Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Apr 18We're Not So Sure You Should Rely on PureTech Health's (LON:PRTC) Statutory Earnings
Jan 18Is PureTech Health plc (LON:PRTC) Popular Amongst Insiders?
Nov 24
Shareholder Returns
| PRTC | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 1.7% | -0.2% | 2.3% |
| 1Y | 1.7% | -29.5% | 0.6% |
Return vs Industry: PRTC exceeded the UK Biotechs industry which returned -29.8% over the past year.
Return vs Market: PRTC exceeded the UK Market which returned 0.3% over the past year.
Price Volatility
| PRTC volatility | |
|---|---|
| PRTC Average Weekly Movement | 6.4% |
| Biotechs Industry Average Movement | 6.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: PRTC has not had significant price volatility in the past 3 months.
Volatility Over Time: PRTC's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 111 | n/a | www.puretechhealth.com |
PureTech Health plc, a clinical stage biotherapeutics company, engages in the discovery, development, and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, currently under Phase 3 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, to inhibit the activity of galectin-9 for treating solid tumors and hematological malignancies. It is also developing LYT-300, an oral allopregnanolone, currently completed Phase 1 stage, to treat depression, anxiety, and related indications; and LYT-310, an oral cannabidiol, currently under preclinical stage, to treat epilepsies and other neurological indications.
PureTech Health plc Fundamentals Summary
| PRTC fundamental statistics | |
|---|---|
| Market cap | UK£574.19m |
| Earnings (TTM) | -UK£37.72m |
| Revenue (TTM) | UK£9.42m |
61.0x
P/S Ratio-15.2x
P/E RatioIs PRTC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PRTC income statement (TTM) | |
|---|---|
| Revenue | US$11.74m |
| Cost of Revenue | -US$31.43m |
| Gross Profit | US$43.17m |
| Other Expenses | US$90.18m |
| Earnings | -US$47.01m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Apr 25, 2024
| Earnings per share (EPS) | -0.17 |
| Gross Margin | 367.81% |
| Net Profit Margin | -400.56% |
| Debt/Equity Ratio | 20.8% |
How did PRTC perform over the long term?
See historical performance and comparison